Interactive Features

True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...

True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...

True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...

True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...

True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.

True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.

True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.

True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...